Close Menu
    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram
    BusinessNewsAsia.comBusinessNewsAsia.com
    Subscribe
    • Home
    • Top Stories
    • Business
    • Tech
    • Companies
    • Events
    • Announcements
    BusinessNewsAsia.comBusinessNewsAsia.com
    Home»BioTech»Captiva Verde Land Corp. Announces Solargram Farms’ Completion of Successful New Brunswick Outdoor Cannabis Harvest with One of the Highest Reported THC and Terpene Values in Canada
    BioTech

    Captiva Verde Land Corp. Announces Solargram Farms’ Completion of Successful New Brunswick Outdoor Cannabis Harvest with One of the Highest Reported THC and Terpene Values in Canada

    Marie JonesBy Marie JonesNovember 30, 2020No Comments4 Mins Read
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Captiva Verde Land Corp. (CSE: PWR) (the “Company”), is extremely pleased to announce that Solargram Farms Corporation (“Solargram”), a holder of a Federal Health Canada License to cultivate, test, harvest and sell cannabis, has successfully completed its first large scale cannabis outdoor farm harvest with record THC and terpene results.

    First Year Harvest Results

    The Solargram cannabis harvest began on September 17th and was completed on October 30th with final processing completed on November 27, 2020. The Solargram team is credited with a final harvest of approximately 13,000 plants over 350,000 square feet of outdoor farm grown canopy resulting in 15,000 kg of wet cannabis. This harvest is ranked as one of Canada’s top single largest, and lowest cost outdoor legal cannabis crop in Canadian history and is also the largest outdoor cannabis crop ever grown and harvested in New Brunswick.

    Very Low Cost of Production Results

    Exceeding expectations, the year one total grow cost of production, including direct labor and direct materials, were CDN $0.05/gram wet; $0.22/gram dry which ranks as one of the top tier, lowest cost of cannabis production facilities in the Canadian cannabis industry.

    Cannabis is a commodity within the CPG (consumer packaging goods) industry. Lowest cost and highest quality wins. Solargram is a major market disruptor and differentiator as its high quality, very low cost of production, allows its planned high cannabinoid full spectrum and distillate oil products to be sold at prices that are produced at a fraction of its competitors’ cost of production. This competitive advantage will allow Solargram to become a leader in the Canadian cannabis market place commencing in 2021.

    HIGH THC REPORTED – Independent Laboratory Test Results

    Solargram produced and harvested approximately 35 genetics of which its R2 strain, representing 65% of its year one outdoor cannabis crop, produced a COA (certificate of analysis) from an independent laboratory supplier at 21.53% THC and 2.7% terpenes.

    The independent THC laboratory results received for the top five genetics produced, representing the harvested crop include:

    R2 (21.53%); Bitter Cherry Punch (18.81%); Gelatoz (17.59%);
    Black Garlic (18.86%); New York Purple Diesel (19.66%)

    These significant high THC results rival and/or exceed indoor cannabis grown facilities in Canada. Independent test results also validate the crop is pesticide and heavy metal free.

    100% of the Solargram shares are held in an escrow account to be transferred to Captiva Verde in exchange for 35 Million Captiva Verde shares subject to a tight pooling agreement, and subject to Health Canada approving an in-process application by all the Captiva Verde Officers and Directors to pass a security clearance and CSE approval.

    On Behalf of the Board of Directors
    “Jeff Ciachurski”
    Jeffrey Ciachurski
    Chief Executive Officer and Director
    Cell: (949) 903-5906
    E-mail: westernwind@shaw.ca

    Cautionary Note Regarding Forward-Looking Information

    This release includes certain statements that may be deemed “forward-looking statements”. All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management’s beliefs, estimates or opinions, or other factors, should change.

    To view the source version of this press release, please visit https://www.newsfilecorp.com/release/69147

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Previous ArticleSingapore: Non-Bank Financial Institutions to have Access to FAST and PayNow
    Next Article Shineway Pharmaceutical (2877.HK) recorded 29.4% revenue growth for October 2020

    Related Posts

    Everest Medicines Secures Exclusive License for Sumecigrel in Asia-Pacific, Expanding Its Cardiovascular Product Portfolio

    June 9, 2026

    Hua Medicine Advances Glucose Homeostasis Platform at ADA 2026, Showcasing Dorzagliatin’s Potential Across Metabolic Disease

    June 9, 2026

    CMS’s (867.HK/8A8.SG) Self-developed Innovative INHBE-Targeting siRNA Drug CMS-D008 Presents Its Preclinical Results at the ADA Scientific Sessions

    June 8, 2026
    Add A Comment

    Comments are closed.

    © 2026 BusinessNewsAsia.com
    • About Us
    • Contact Us
    • BusinessNews.ph
    • AsiaPEVC.com
    • DevFiNews.com
    • RenewableEnergy.ph

    Type above and press Enter to search. Press Esc to cancel.